Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYL040012 in subjects with elevated IOP
NCT01227291Phase 2Completed
- Sponsor
- Sylentis
- Start
- Oct 2010
- Primary completion
- Mar 2012
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bamosiran in Glaucoma and ocular hypertension, sponsored by Sylentis. Primary endpoint: Tolerance on ocular surface (ocular and conjunctiva) at 8 days. Started Oct 2010; status: completed.
02
Drugs
bamosiran
03
Conditions
Glaucomaocular hypertension
Beyond the preview
Go deeper on NCT01227291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01227291.